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We recently described the construction of a feline herpesvirus-1 (FHV-1) recombinant vaccine strain, FHVb-galgIgED,
containing a deletion in both the gI and the gE genes. We also reported comparative tests of its safety and efficacy in cats.
These cats were unvaccinated or subcutaneously vaccinated with FHVb-galgIgED, its isotypic parent strain (FHV-1SA), or
a commercial FHV-1 vaccine strain (FHV-1CV) and subsequently challenged with a virulent field strain of FHV-1. Here we
report the determination of FHV-1 field virus latency load after challenge in the same experimental animals. FHV-1 specific
quantitative PCR was carried out on feline genomic DNA isolated from trigeminal ganglia, olfactory bulbs, and brain stems.
We have determined that a reduction in field virus latency load in cats vaccinated subcutaneously with wild-type FHV-1
strains prior to challenge is dependent upon glycoproteins gI and gE deleted in FHVb-galgIgED. q 1997 Academic Press
Sites of primary alphaherpesvirus infection include the route (10, 11). While FHVb-galgIgED administered via
ocular, oronasal, and urogenital epithelia, depending the subcutaneous route effectively reduced clinical signs
upon the virus species and its tropism. As the acute due to virulent challenge, vaccine administration via the
infection progresses, virus is transported across syn- oronasal route provided significantly better protection.
apses into neurons that innervate the epithelial mucosae We also showed that FHV-1CV, a representative commer-
(1). Latent infection of the nervous system after the acute cially available subcutaneously administered vaccine
phase of infection is common to all alphaherpesviruses strain, was effective by the subcutaneous route, but
(2). Furthermore, latent HSV-1,2, VZV, PRV, BHV-1, EHV- highly virulent when administered oronasally (11). It has
1, and feline herpesvirus-1 (FHV-1) have been character- been suggested that such FHV-1 vaccines are not viru-
istically isolated from the trigeminal ganglia of their re- lent when administered subcutaneously because they do
spective host species (1, 3–7). not replicate as efficiently at the cat’s normal core body
Feline herpesvirus-1, an alphaherpesvirus, is a signifi- temperature as at cooler sites in the upper respiratory
cant pathogen limited to the family Felidae. FHV-1 primar- tract (12).
ily affects the upper respiratory system of cats. Ocular As part of this study we have quantitated latent wild-
disease, abortion in pregnant queens, neurological disor- type FHV-1 in the trigeminal ganglia, olfactory bulbs, and
ders, and virus generalization, with mortality reaching brain stem of cats either unvaccinated or subcutaneously
50% in kittens, have also been observed. Lifelong latent vaccinated with FHV-1CV, FHVb-galgIgED, or FHV-1SA
infection follows acute respiratory disease, and reacti- prior to challenge with a virulent field strain of FHV-1.
vated latent FHV-1 plays an important role in virus perpet- Twenty-one and seven days prior to oronasal challenge
uation and spread (8). Frequently, during periods of with 106 TCID50 of FVR-SGE, a virulent challenge strain
stress such as change of housing, queening, or lactation, provided by the USDA, three randomly chosen groups of
latent virus can reactivate. Although clinical signs may be five specific pathogen-free cats were each inoculated
absent or mild, recrudescent animals can shed infectious subcutaneously with 107 TCID50 of FHV-1CV, FHV-1SA, or
virus for up to 1 week (9). FHVb-galgIgED. Virus neutralization (VN) titers following
Previously we described the construction of FHVb- subcutaneous vaccination as previously described were
galgIgED and showed that this strain was efficacious moderate with no significant differences between VN ti-
when administered by the subcutaneous or oronasal ters induced by any of the inoculated strains (11). Post-
challenge clinical scores and virus shedding were sub-
stantially reduced in immunized cats compared to control1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (517) 353-4426. E-mail: Maes@AHDLMS.CVM.MSU.EDU. cats. Cats receiving FHVb-galgIgED had a higher fre-
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FIG. 1. Locations of specific primer and probes used for wild-type FHV-1 QPCR assay. (A) Diagram of the FHV-1 genome. UL , unique long region;
IR , internal repeat (hatched box); US , unique short region; TR , terminal repeat (hatched box). E, EcoRI restriction site; S, SalI restriction site; and H,
HindIII restriction site. (B) Expanded view of unique short region. Glycoprotein genes are depicted as boxes. Hatched area represents the region
deleted in FHVb-galgIgED. (C) Location of upstream biotinylated primer, downstream primer, and TBR-labeled probe used for the wild-type FHV-1
QPCR assay. Sequences above the line are sense-strand coding. Those below the line are antisense-strand coding.
quency of virus shedding than FHV-1SA or FHV-1CV vac- it did not introduce any potential PCR inhibitors to iso-
lated nucleic acids (data not shown) (13).cinees (11). Methods used for the care of cats prior to
vaccination, for vaccination with FHV-1CV and FHVb- We previously described a PCR assay for the FHV-1
gE gene that detects as few as 400 genomes of a FHV-galgIgED, and for challenge with a field virus strain have
previously been described (10). Eight weeks after orona- 1 gE/ strain in 0.1 mg of total cellular DNA with ethidium
bromide staining of a 478-bp PCR product electropho-sal challenge with virulent FHV-1 (FVR-SGE), cats were
anesthetized by subcutaneous inoculation of ketamine resed on an agarose gel (10). The locations and se-
quences of primers used are depicted in Fig. 1. This PCRhydrochloride and acepromazine maleate and then hu-
manely euthanized with an overdose of pentabarbital so- amplification was adapted for electrochemiluminescent
quantitation of latent FHV-1 in feline tissue samples. Fordium administered by intracardiac injection. Prior to eu-
thanasia virus shedding was assessed in all cats. No the quantitative assay, a 478-bp fragment of the FHV-1
gE gene was amplified using an upstream biotinylatedevidence of viral reactivation was found. Trigeminal gan-
glia were harvested by sharp excision of tissue located primer (Fig. 1). Biotinylation enabled the capture of spe-
cific PCR products on streptavidin-coated magneticin the cavum trigeminale of the dura mater lateral to the
cavernous sinus at the apex of the petrous temporal beads. A 35-bp DNA probe (5*-CAAAAAATGTGAAGTTTT-
GTTTAAAGGTGGGTCGA-3*) with TBR (tris(2*,2*-bipyri-bone. After collection, these tissues were immediately
frozen in liquid nitrogen, placed in cryogenic storage dine)-ruthenium(II) chelate) attached to the 5*-end and
sequence complementary to the wild-type FHV-1 strainsvials, and stored at 0807. Tissues were divided in half
prior to DNA isolation. Total DNA from each of the four including FVR-SGE, FHV-1CV, and FHV-1SA provided a
wild-type specific electrochemiluminescent reporter (Fig.pieces was isolated by proteinase K and detergent dis-
ruption of tissue followed by silica gel spin-column purifi- 1). Post-PCR hybridization of the reporter probe to the
biotinylated PCR product strand was done for 15 min atcation as described by the manufacturer (Qiamp kit; Qia-
gen, Inc.). Total genomic DNA was also isolated from 557 after a brief denaturation at 947 for 5 min. Excess
streptavidin-coated magnetic beads (Dynal, M450) wereolfactory bulbs and brain stem tissue. Although other
DNA isolation methods were attempted, the silica gel added to the hybridization mixture, which was incubated
an additional 15 min at 557. The entire mixture was di-column method (Qiamp; Qiagen, Inc.) was used because
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DNA were also assayed with no added TG DNA. In addi-
tion, known concentrations of FHV-1 genomic DNA com-
parable to those used to construct the standard curve in
Fig. 2 were accurately quantitated in ‘‘spiked’’ solutions
containing as much as 5 mg of TG, olfactory bulb, or brain
stem total DNA (data not shown).
In this study, FHV-1 latency load was determined as FHV-
1 genome equivalents per microgram of TG DNA. Estimates
of the number of latent FHV-1 genomes/100 cells are based
on the following analysis. Assuming the haploid feline ge-
nome contains on the order of 3.5 1 109 bp (16), and each
DNA base pair has a molecular weight of approximately
660 Da (Avogadro’s number  6.023 1 1023 molecules/g
molecular weight equivalent), it can be determined that one
haploid genome weighs approximately 3.8 pg and 1 mg
of feline genomic DNA will contain approximately 260,000
haploid genome equivalents. In order to calculate the num-
ber of FHV-1 genomes per cell, we have also assumed
that ganglionic cells are diploid.
Latent FHV-1 was recovered at significantly higher
FIG. 2. FHV-1 virion DNA standard curve. Six sets of serial dilutions concentrations in trigeminal ganglia from cats that were
containing known concentrations of highly purified FHV-1 virion DNA
either not vaccinated or vaccinated subcutaneously withwere assayed in the presence or absence of 105 ng of TG DNA using
FHVb-galgIgED than in ganglia from cats that were vac-the quantitative PCR assay described in the text. The average luminos-
ity value and standard deviation for each dilution of the three sets cinated with either FHV-1SA or FHV-1CV (P 0.01; Table
assayed in the presence of TG DNA is depicted as s—, where standard 1; F-test) (17). Only extremely low levels (1–23 copies/
deviation is indicated by the vertical bar. The average luminosity values 130,000 cells) of FHV-1 DNA were detected in either ol-
and standard deviations for each dilution of three sets of FHV-1 virion
factory bulbs or brain stem tissue.DNA assayed in the absence of TG DNA are depicted as L—, with
There is an approximately 10-fold difference betweenstandard deviation indicated by the vertical apices of the diamond.
Electrochemiluminescence was measured in luminosity units. FHV- the mean field virus latency load after challenge of cats
1 genomic copy number was determined by spectrophotometric and subcutaneously vaccinated with the parent or commercial
fluorimetric analysis of virion DNA prior to dilution. Luminosity values FHV-1 strains and that of those subcutaneously vaccinated
for ‘‘with and without’’ TG DNA sets were normalized to the manufactur-
with FHVb-galgIgED (Table 1). Since only the gI and gEer’s standards (CV  5%) at the 103 genome equivalent value to adjust
genes have been interrupted in FHVb-galgIgED, thesefor instrument drift and recalibration between the two series of assays.
FHV-1 virion DNA was isolated as previously described (10). genes or their glycoprotein products must play a role in
reducing the field virus latency load after challenge in the
trigeminal ganglia of FHV-1CV and FHV-1SA vaccinees.
luted to 0.7 ml with buffer containing tripropylamine, an Previously we showed that FHV-1 vaccine strains lack-
electrochemiluminescent activator. The QPCR assay was ing glycoproteins gI and gE produce plaques of reduced
carried out in an automated electrochemiluminescence size compared to those of the wild-type strain FHV-1SA,
detector (Perkin–Elmer QPCR 5000) (14). suggesting that the mutant virus spreads poorly by syncy-
Initial sample FHV-1 DNA concentration was deter- tium formation (10). It was also determined that subcuta-
mined by interpolation of a standard curve. A standard neously inoculated FHV-1SA was invasive, could spread
curve was prepared for each set of tissue samples as- from the inoculation site to epithelial tissues, and could
sayed by amplifying and determining the luminosity asso- produce a productive infection that resulted in detectable
ciated with known initial FHV-1 genomic DNA concentra- virus shedding (10). Vaccine virus spread from the subcu-
tions (15). Specific detection of FHV-1 DNA was not sig- taneous inoculation site may be required for protection
nificantly affected by the presence of cellular DNA. Figure against field virus colonization of the trigeminal ganglion
2 depicts standard curve data from six separate QPCR in subcutaneously vaccinated cats after challenge and
assays performed in the presence or absence of added may explain the inability of FHVb-galgIgED to protect
feline trigeminal ganglionic (TG) DNA. In one series of against it. In this study the influence of vaccine strain
experiments, three serial dilution sets each containing latency (precolonization of the trigeminal ganglia) on pro-
1, 10, 102, 103, 104, and 105 genome equivalents of puri- tection from field virus latency after challenge in FHV-
fied FHV-1 virion DNA were individually prepared, com- 1CV and FHV-1SA vaccinees could not be established,
bined with a constant amount of TG DNA (105 ng), and since latent virus detected in both FHV-1CV and FHV-
assayed. Three serial dilution series containing 1, 10, 1SA vaccinees could be either vaccine or challenge virus
(18). It is also possible that stimulation of a mucosal or102, and 103 genome equivalents of purified FHV-1 virion
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TABLE 1
Latency Load in Tissues of Previously Immunized Cats after Virulent FHV-1 Challenge
Trigeminal ganglion Olfactory bulb Brain stem
Mean latency load Latent Mean latency load Latent Mean latency load Latent
Vaccination (FHV-1 genomes/mg FHV-1/100 (FHV-1 genomes/mg FHV-1/100 (FHV-1 genomes/mg FHV-1/100
group N ganglionic DNA)a cellsb olfactory bulb DNA)a cellsb brain stem DNA)a cellsb
FHV-1CV 5 926 { 1,634 (3,825) 0.71 18.20 { 30 (69) 0.014 2.06 { 3 (7) 0.002
FHVb-galgIgED 5 7,211 { 10,799 (26,303) 5.5 14.40 { 15 (36) 0.011 16.40 { 14 (34) 0.013
FHV-1SA 5 565 { 576 (1,188) 0.43 10.40 { 7 (15) 0.008 1.0 { 2 (5) 0.001
Unvaccinated 5 7,276 { 15,843 (35,595) 5.6 23.40 { 24 (60) 0.018 4.14 { 4 (10) 0.003
a Average latency load was determined for all cats by QPCR analysis of feline genomic DNA extracted from nervous tissue and is shown with
the standard deviation. The range is in parentheses.
b Based on 260,000 haploid genome equivalents/mg of feline cellular DNA.
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